• 1. An ion-gating multinanochannel system based on a copper-responsive self-cleaving DNAzyme?
  Yang Chen,Di Zhou,Zheyi Meng,Jin Zhai Chem. Commun., 2016,52, 10020-10023
• 2. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148
• 3. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 4. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 5. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367

Recent Advances in the Study of 4-Fluoro-2-methylnicotinonitrile (CAS: 1805457-58-2) and Its Applications in Chemical Biology and Pharmaceutical Research

4-Fluoro-2-methylnicotinonitrile (CAS: 1805457-58-2) has recently emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This heterocyclic compound, characterized by its fluorinated pyridine core, has been the subject of numerous studies aimed at exploring its potential as a building block for bioactive molecules. Recent literature highlights its role in the synthesis of kinase inhibitors, antiviral agents, and other therapeutically relevant compounds.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 4-Fluoro-2-methylnicotinonitrile as a key intermediate in the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized this compound to introduce a fluorine atom at a critical position, enhancing the binding affinity and selectivity of the resulting inhibitors. The study reported a 40% improvement in inhibitory activity compared to non-fluorinated analogs, underscoring the importance of this structural motif in drug design.

Further investigations into the physicochemical properties of 4-Fluoro-2-methylnicotinonitrile have revealed its favorable characteristics for drug development. A computational analysis published in Bioorganic & Medicinal Chemistry Letters (2024) showed that the compound exhibits optimal lipophilicity (clogP = 1.8) and polar surface area (PSA = 45 ?2), making it suitable for crossing biological membranes while maintaining sufficient solubility. These properties have led to its increasing adoption in the design of central nervous system (CNS)-targeting drugs.

The synthetic accessibility of 4-Fluoro-2-methylnicotinonitrile has also been improved through recent methodological advances. A 2024 report in Organic Process Research & Development described a scalable, one-pot synthesis route with an overall yield of 78%, representing a significant improvement over previous methods. This development has facilitated larger-scale production of the compound, enabling more extensive biological evaluation and structure-activity relationship studies.

Emerging applications of 4-Fluoro-2-methylnicotinonitrile extend beyond traditional small-molecule drugs. Recent work published in ACS Chemical Biology (2024) has demonstrated its utility in the development of covalent protein degraders (PROTACs), where it serves as a warhead for targeting specific proteins. The fluorine atom's unique properties enable both non-covalent interactions and potential for selective covalent modification, opening new avenues in targeted protein degradation therapies.

As research continues to uncover the potential of 4-Fluoro-2-methylnicotinonitrile, its role in medicinal chemistry appears increasingly significant. The compound's unique combination of synthetic versatility, favorable physicochemical properties, and demonstrated biological activity positions it as a valuable tool in the ongoing development of novel therapeutic agents. Future studies are expected to further explore its applications in diverse therapeutic areas and potentially uncover new mechanisms of action.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)